New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 21, 2020 - Sunovion Pharmaceuticals announced the FDA approval of Kynmobi (apomorphine), for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease.
Download PDF
Return to publications
